Gossamer Bio, Inc. (NASDAQ:GOSS) Given Average Recommendation of “Moderate Buy” by Analysts

Gossamer Bio, Inc. (NASDAQ:GOSS) has earned an average rating of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $8.50.

A number of equities analysts recently weighed in on the stock. Scotiabank assumed coverage on shares of Gossamer Bio in a research note on Monday, July 14th. They set a “sector outperform” rating and a $11.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Gossamer Bio in a research report on Wednesday, October 8th. Cantor Fitzgerald reissued an “overweight” rating on shares of Gossamer Bio in a research report on Thursday, September 11th. Wall Street Zen downgraded Gossamer Bio from a “hold” rating to a “sell” rating in a report on Sunday, September 21st. Finally, Wedbush lifted their target price on Gossamer Bio from $4.00 to $5.00 and gave the stock an “outperform” rating in a report on Wednesday, August 6th.

Institutional Trading of Gossamer Bio

Several hedge funds have recently modified their holdings of GOSS. Drive Wealth Management LLC increased its stake in Gossamer Bio by 52.7% in the second quarter. Drive Wealth Management LLC now owns 25,474 shares of the company’s stock valued at $31,000 after purchasing an additional 8,797 shares in the last quarter. Ciovacco Capital Management LLC bought a new stake in Gossamer Bio in the third quarter valued at $27,000. Brighton Jones LLC bought a new stake in Gossamer Bio in the third quarter valued at $36,000. Wealth Enhancement Advisory Services LLC bought a new stake in Gossamer Bio in the 3rd quarter valued at about $48,000. Finally, Legal & General Group Plc bought a new stake in Gossamer Bio in the 2nd quarter valued at about $26,000. Institutional investors own 81.23% of the company’s stock.

Gossamer Bio Price Performance

Shares of GOSS opened at $2.39 on Thursday. Gossamer Bio has a 1 year low of $0.66 and a 1 year high of $3.60. The business has a 50-day moving average of $2.62 and a 200-day moving average of $1.80. The company has a market capitalization of $543.44 million, a price-to-earnings ratio of -3.85 and a beta of 1.94.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.01. Gossamer Bio had a negative net margin of 344.81% and a negative return on equity of 1,774.72%. The firm had revenue of $11.49 million during the quarter, compared to analyst estimates of $4.12 million. As a group, sell-side analysts anticipate that Gossamer Bio will post -0.28 EPS for the current year.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.